The aim of this research is to determine which volatile organic compounds (odors) are associated with different skin cancers.
To this end, odor samples will be taken from various parts of the body, from patients with skin cancers and from "healthy" subjects who have no skin cancer.
The various samples collected will be analyzed in the laboratory, and compared with each other, to determine whether there is a specific "smell" for the main types of skin cancer.

Start Date25 Jul 2024

Sponsor / Collaborator-

NCT06042075 / Not yet recruitingNot ApplicableIIT

Representation of Congenital Birthmarks in Newborns by Angers Maternity Unit Health Professionals

This descriptive cross-sectional single center study will be conducted at Angers Maternity Unit.
It pertains to the ways in which healthcare professionals represent congenital birthmarks found in newborns.
It is our assumption that health professionals may have a tendency to engage in inappropriate behavior when dealing with congenital birthmarks due to lack of knowledge. We make the presumption that insufficient knowledge causes difficulties in managing these birthmarks.
Data as to representation of birthmarks in newborns by health professionals will be collected using a semi-quantitative questionnaire.
This study constitutes preliminary research work, with a view to creating a professional development plan if necessary.

Start Date01 Oct 2023

Sponsor / Collaborator

Centre Hospitalier Universitaire d'Angers

JPRN-UMIN000049697 / RecruitingIIT

Investigation of deodorizing effects of sofpyrronium bromide gel agent - Investigation of deodorizing effects of sofpyrronium bromide gel agent

Start Date19 Dec 2022

Sponsor / Collaborator

Shimane University

100 Clinical Results associated with Odour body

100 Translational Medicine associated with Odour body

0 Patents (Medical) associated with Odour body

899

Literatures (Medical) associated with Odour body

16 Sep 2024·International journal of cosmetic science

Identification of a higher C-S lyase activity of Staphylococcus hominis in volunteers with unpleasant axillary odour.

Article

Author: Aymard, Elodie ; Richer, Stéphanie ; Grimaldi, Christine ; Gilardeau, Sophie ; Laspoussas, Aliette ; Le Guillou, Maud ; Closs, Brigitte ; Verzeaux, Laurie ; Muchico, Hélène ; Guedj, Océane

OBJECTIVEExcessive and unpleasant odours that emanate from the skin can induce bromhidrosis and substantially impair a person's quality of life. Enzymatic pathways generating unpleasant odours are well detailed, and among them, the C-S lyase is one of the enzymes involved in the conversion of non-volatile precursors into thiol-type malodorous volatile molecules such as 3M3SH. This study aimed to investigate the variation of axillary odour intensity correlated with Staphylococcus (S.) hominis C-S lyase activity within a group of volunteers after a physical activity.METHODSFirst, a group of 24 volunteers from the same ethnicity with standardized hygienic and alimentary practices participated in a supervised indoor cycling activity. Following this session, worn T-shirts were recovered to enable the olfactory evaluation of axillary odours by qualified experts. To go further, the microbiota from the axillary zone of each volunteer was sampled and the bacterial relative abundance was investigated by using 16S rRNA metasequencing. Then, S. hominis isolates were obtained by culturomics from these microbiota samples and the C-S lyase activity was measured by spectrofluorometry in protein crude extracts.RESULTSThe evaluation of the odour intensity revealed that within the panel, two groups were significantly distinct. A non-odorous group and a malodorous one with volunteers having unpleasant odours. The 16S rRNA metasequencing reveals differences in bacterial communities between the two groups with a significant increase in the relative abundance of S. hominis in the malodorous group compared with the non-odorous one. The C-S lyase activities measured on S. hominis sampled on volunteers from the two groups demonstrate that for an equivalent quantity of protein, this enzymatic activity is significantly higher for the samples originating from the malodorous group.CONCLUSIONHence, this study demonstrates that beyond the increase of S. hominis relative abundance, the C-S lyase enzymatic activity of this bacteria is also higher in volunteers with unpleasant axillary odours.

01 Sep 2024·Respiratory Medicine

The roles of bacteria and viruses in COPD-Bronchiectasis association: A prospective cohort study

Article

Author: Zhong, Nan-Shan ; Lin, Sheng-Zhu ; Pan, Cui-Xia ; He, Zhen-Feng ; Huang, Yan ; Zhang, Xiao-Xian ; Shi, Ming-Xin ; Lin, Zhen-Hong ; Chen, Chun-Lan ; Cen, Lai-Jian ; Zha, Shan-Shan ; Chen, Zhao-Ming ; Guan, Wei-Jie ; Li, Hui-Min

BACKGROUNDExacerbations are implicated in bronchiectasis and COPD, which frequently co-exist [COPD-Bronchiectasis association (CBA)]. We aimed to determine the bacterial and viral spectrum at stable-state and exacerbation onset of CBA, and their association with exacerbations and clinical outcomes of CBA as compared with bronchiectasis.METHODSWe prospectively collected spontaneous sputum from adults with CBA, bronchiectasis with (BO) and without airflow obstruction (BNO) for bacterial culture and viral detection at stable-state and exacerbations.RESULTSWe enrolled 76 patients with CBA, 58 with BO, and 138 with BNO (711 stable and 207 exacerbation visits). Bacterial detection rate increased from BNO, CBA to BO at steady-state (P = 0.02), but not at AE onset (P = 0.91). No significant differences in viral detection rate were found among BNO, CBA and BO. Compared with steady-state, viral isolations occurred more frequently at exacerbation in BNO (15.8 % vs 32.1 %, P = 0.001) and CBA (19.5 % vs 30.6 %, P = 0.036) only. In CBA, isolation of viruses, human metapneumovirus and bacteria plus viruses was associated with exacerbation. Repeated detection of Pseudomonas aeruginosa (PA) correlated with higher modified Reiff score (P = 0.032) in CBA but not in BO (P = 0.178). Repeated detection of PA yielded a shorter time to the first exacerbation in CBA [median: 4.3 vs 11.1 months, P = 0.006] but not in BO (median: 8.4 vs 7.6 months, P = 0.47).CONCLUSIONSIsolation of any viruses, human metapneumovirus and bacterialplus viruses was associated with CBA exacerbations. Repeated detection of PA confers greater impact of future exacerbations on CBA than on BO.

01 Sep 2024·Aesthetic Plastic Surgery

Intraoperative Hypertonic Saline Irrigation Preventing Seroma Formation in the Treatment of Axillary Bromhidrosis

Article

Author: Xie, Shao ; Wang, Yu

PURPOSESubcutaneous seroma formation (SF) is commonly seen after axillary bromhidrosis surgeries and its treatment can be challenging and long. Current prevention methods are not consistent, and the treatment includes repeated aspirations and drains, both are associated with higher risk for infections. The purpose of this article is to present a novel and simple technique of intraoperative hypertonic saline irrigation (IHSI) to axillary bromhidrosis subcutaneous dead space, which prevents postoperative SF and enables early drain removal due to reduced secretions.METHODSFrom 2015 to 2022, we performed the intraoperative irrigation of the cavity through normal saline in 100 patients with primary axillary bromhidrosis. Through an incision approximately 3 cm long at the central axillary crease, the entire subcutaneous tissues containing apocrine glands were initially dissected with straight scissors within the axillary area, and then, the undermined apocrine glands were removed with curved scissors. The skin was defatted to become a full-thickness skin flap. Any suspected hemorrhagic spots were immediately coagulated electrosurgically. Negative pressure drains were placed, and intraoperative irrigation of the cavity through the drains with 20 ml of NaCl 0.9% or NaCl 10% left at site for 10 min applies different saline solutions in the same patients.RESULTSThe volume of drainage on the 1st postoperative day was 6.54±0.36 mL for the group B, which was significantly less than 15.23±0.42 mL for the group A (p < 0.05). The time of drain removal for the group B was 24 h, which was shorter than 48 h for the group A. In group B, 4 percent of axillae showed significant SF postoperatively, which was lower than the 20 percent of axillae associated with the group A (p < 0.05). The rate of incision infection for the group B was 2 percent, which was significantly lower than the 6 percent of axillae in the group A (p < 0.05). Two percent of axillae showed skin edge necrosis postoperatively in the group B, which was lower than the 10 percent of axillae associated with the group A (p < 0.05).CONCLUSIONSIHSI enhances adhesion formation and reduces secretion rate in subcutaneous dissection space after axillary bromhidrosis surgeries, therefore enables early drain removal and prevents SF, incision infection and skin edge necrosis. As a result, reducing the pain of patients, decreasing inconveniency and cost saving of multiple outpatient visits or additional surgery.LEVEL OF EVIDENCE IIThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

News (Medical) associated with Odour body

09 Nov 2022

·www.prnewswire.com

Bromhidrosis Disease Treatment Market Size to Grow by 362.76 Mn, Increasing Number of M&A by Vendors to be a Key Trend - Technavio

NEW YORK, Nov. 9, 2022 /PRNewswire/ -- The bromhidrosis disease treatment market size is expected to grow by USD 362.76 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 8.92% during the forecast period, according to Technavio. The market has been segmented by type geography (North America, Europe, Asia, and Rest of World (ROW) and (apocrine body odor and eccrine body odor). Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample report is available in PDF format Continue Reading Technavio has announced its latest market research report titled Global Bromhidrosis Disease Treatment Market 2022-2026 The rise in the number of patients affected by diabetes and kidney diseases, government awareness programs about the disease, and an increase in healthcare affordability in the US are some of the major factors propelling the market growth. However, factors such as the high cost of treatment, rise in the cost of R&D activities, and lack of knowledge of the disease will hamper the market growth. More details: Bromhidrosis Disease Treatment Market: Trend The increasing M&As is a key trend shaping the bromhidrosis disease treatment market. The key vendors are acquiring small vendors to gain access to new products and technologies at low costs. For instance, in February 2022, Ipsen Pharma partnered with Mayoly Spindler to sell its global consumer healthcare business. In May 2022, Pfizer Inc. announced the acquisition of Biohaven Pharmaceutical Holding Company Ltd. In January 2022, Novartis AG partnered with Alnylam to work on targeted therapy to restore liver function. Thus, the rise in the number of M&A will support the growth of the market in the coming years. Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. Buy Now for detailed information about market dynamics Bromhidrosis Disease Treatment Market: Type Landscape By type, the apocrine body odor segment will be a significant contributor to market growth during the forecast period. Apocrine sweat, when discharged, is colorless and odorless. In apocrine bromhidrosis, body odor is caused due to the combination of lipid-rich apocrine gland perspiration with microorganisms on the skin. This leads to the formation of thioalcohol. Thus, the increase in the number of people with apocrine bromhidrosis will drive the growth of the segment during the forecast period. Bromhidrosis Disease Treatment Market: Geographic Landscape By geography, North America is going to have lucrative growth during the forecast period. About 38% of the market's overall growth is expected to originate from the region. The US and Canada are the key markets for bromhidrosis disease treatment in North America. The growth of the market in the region is attributed to factors such as rising healthcare expenditures, a well-developed healthcare sector, a large patient population, and government backing for R&D. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report Bromhidrosis Disease Treatment Market: Companies Covered AbbVie Inc. - The company offers bromhidrosis disease treatment, namely Botox. Galderma SA - The company offers bromhidrosis disease treatment, namely Alluzience. Hikma Pharmaceuticals Plc - The company offers bromhidrosis disease treatment, namely Glycopyrrolate injection. Ipsen Pharma - The company offers bromhidrosis disease treatment, namely Dysport. Biovencer Healthcare Pvt. Ltd. Johnson & Johnson - The company offers bromhidrosis disease treatment, namely Ditropan XL, through its subsidiary Janssen. Boehringer Ingelheim International GmbH Journey Medical Corp. Medytox Inc. Merz Pharma GmbH & Co. KGaA Novartis AG Pfizer Inc. Bromhidrosis Disease Treatment Market: What our reports offer Market share assessments for the regional and country-level segments Strategic recommendations for the new entrants Covers market data from 2021 to 2026 Market trends (threats, challenges, drivers, investment opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping recording the key common trends Company profiling with financials, detailed strategies, and recent developments Supply chain trends mapping the latest technological advancements Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed annually at USD 5000 Related Reports Gastrointestinal Diseases Therapeutics Market by Drug Class and Geography - Forecast and Analysis 2022-2026: The increasing incidence of gastrointestinal diseases is driving market growth. Gastrointestinal diseases have increased significantly across the globe. Improper diet, inactive lifestyle, stress, food sensitivity, and bacterial or viral infection are the major factors contributing to the increasing incidence of chronic and acute gastrointestinal diseases. Celiac Diseases Drugs Market by Therapy Type and Geography - Forecast and Analysis 2022-2026: Higher consumption of gluten-containing food is driving the market growth. Celiac disease is characterized by an increase in gluten deposition in the body due to the high consumption of food containing gluten. Pizza, cake, soups, beer, bread, cookies, pasta, and burgers are some of the widely consumed food that contains gluten. Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Apocrine body odor - Market size and forecast 2021-2026 Exhibit 28: Chart on Apocrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Apocrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Apocrine body odor - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Apocrine body odor - Year-over-year growth 2021-2026 (%) 5.4 Eccrine body odor - Market size and forecast 2021-2026 Exhibit 32: Chart on Eccrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Eccrine body odor - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Eccrine body odor - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Eccrine body odor - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Canada - Market size and forecast 2021-2026 Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.9 Germany - Market size and forecast 2021-2026 Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.10 China - Market size and forecast 2021-2026 Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%) 7.11 UK - Market size and forecast 2021-2026 Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 AbbVie Inc. Exhibit 85: AbbVie Inc. - Overview Exhibit 86: AbbVie Inc. - Product / Service Exhibit 87: AbbVie Inc. - Key offerings 10.4 Boehringer Ingelheim International GmbH Exhibit 88: Boehringer Ingelheim International GmbH - Overview Exhibit 89: Boehringer Ingelheim International GmbH - Business segments Exhibit 90: Boehringer Ingelheim International GmbH - Key news Exhibit 91: Boehringer Ingelheim International GmbH - Key offerings Exhibit 92: Boehringer Ingelheim International GmbH - Segment focus 10.5 Galderma SA Exhibit 93: Galderma SA - Overview Exhibit 94: Galderma SA - Product / Service Exhibit 95: Galderma SA - Key news Exhibit 96: Galderma SA - Key offerings 10.6 Hikma Pharmaceuticals Plc Exhibit 97: Hikma Pharmaceuticals Plc - Overview Exhibit 98: Hikma Pharmaceuticals Plc - Business segments Exhibit 99: Hikma Pharmaceuticals Plc - Key offerings Exhibit 100: Hikma Pharmaceuticals Plc - Segment focus 10.7 Ipsen Pharma Exhibit 101: Ipsen Pharma - Overview Exhibit 102: Ipsen Pharma - Business segments Exhibit 103: Ipsen Pharma - Key offerings Exhibit 104: Ipsen Pharma - Segment focus 10.8 Johnson and Johnson Exhibit 105: Johnson and Johnson - Overview Exhibit 106: Johnson and Johnson - Business segments Exhibit 107: Johnson and Johnson - Key news Exhibit 108: Johnson and Johnson - Key offerings Exhibit 109: Johnson and Johnson - Segment focus 10.9 Medytox Inc. Exhibit 110: Medytox Inc. - Overview Exhibit 111: Medytox Inc. - Product / Service Exhibit 112: Medytox Inc. - Key offerings 10.10 Merz Pharma GmbH and Co. KGaA Exhibit 113: Merz Pharma GmbH and Co. KGaA - Overview Exhibit 114: Merz Pharma GmbH and Co. KGaA - Product / Service Exhibit 115: Merz Pharma GmbH and Co. KGaA - Key offerings 10.11 Novartis AG Exhibit 116: Novartis AG - Overview Exhibit 117: Novartis AG - Business segments Exhibit 118: Novartis AG - Key offerings Exhibit 119: Novartis AG - Segment focus 10.12 Pfizer Inc. Exhibit 120: Pfizer Inc. - Overview Exhibit 121: Pfizer Inc. - Product / Service Exhibit 122: Pfizer Inc. - Key news Exhibit 123: Pfizer Inc. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 124: Inclusions checklist Exhibit 125: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 126: Currency conversion rates for US$ 11.4 Research methodology Exhibit 127: Research methodology Exhibit 128: Validation techniques employed for market sizing Exhibit 129: Information sources 11.5 List of abbreviations Exhibit 130: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

AcquisitionCollaborate

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis